Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.
NCT05987956 · ACTIVE NOT RECRUITING · Phase 3
We track 1 ClinicalTrials.gov studies led by Han Xu Md Phd Fapcr Sponsor Investigator Irb Chair. The portfolio skews toward Phase 3 (1 trials).
1 clinical trials sponsored by Han Xu Md Phd Fapcr Sponsor Investigator Irb Chair.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 3 | 1 | 100% |
Han Xu Md Phd Fapcr Sponsor Investigator Irb Chair currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 3.
Han Xu Md Phd Fapcr Sponsor Investigator Irb Chair conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.